Cargando…

Evaluation and follow-up of antibody formation after CoronaVac vaccine

OBJECTIVE: The aim of this study was to monitor the time-dependent change by evaluating the antibody levels at the 4th, 7th, 10th, 13th, and 16th weeks after the second dose of the CoronaVac vaccine. METHODS: The study group (n=65) were between 21 and 60 years old and received two doses of the Coron...

Descripción completa

Detalles Bibliográficos
Autores principales: Çalişir, Büşra, Çöplü, Nilay, Yasar-Duman, Melike, Kilinc, Cetin, Ozbek, Ridvan, Demir, Celal, Ergül, Zafer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Médica Brasileira 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779953/
https://www.ncbi.nlm.nih.gov/pubmed/36477105
http://dx.doi.org/10.1590/1806-9282.20221074
_version_ 1784856736427933696
author Çalişir, Büşra
Çöplü, Nilay
Yasar-Duman, Melike
Kilinc, Cetin
Ozbek, Ridvan
Demir, Celal
Ergül, Zafer
author_facet Çalişir, Büşra
Çöplü, Nilay
Yasar-Duman, Melike
Kilinc, Cetin
Ozbek, Ridvan
Demir, Celal
Ergül, Zafer
author_sort Çalişir, Büşra
collection PubMed
description OBJECTIVE: The aim of this study was to monitor the time-dependent change by evaluating the antibody levels at the 4th, 7th, 10th, 13th, and 16th weeks after the second dose of the CoronaVac vaccine. METHODS: The study group (n=65) were between 21 and 60 years old and received two doses of the CoronaVac vaccine. Blood samples were collected after 4th, 7th, 10th, 13th, and 16th weeks of the second dose of the vaccine administration. There was a coronavirus disease 2019 recovered group (n=29) who were SARS-CoV-2 real-time PCR test result positive before the vaccination period, and no coronavirus disease 2019 history group (n=36). Age, BMI, gender, smoking, comorbidity, coronavirus disease 2019 contact history, and working in the coronavirus disease 2019 service history of the individuals were recorded. RESULTS: No statistically significant difference was found in the descriptive findings of the individuals according to coronavirus disease 2019 recovered group and no coronavirus disease 2019 history group. It was observed that antibody levels in the coronavirus disease 2019 recovered group were found to be higher for each period of serum collection compared to the no coronavirus disease 2019 history group, which were statistically significant. The distribution curves of the antibody levels according to the timing of blood collection in coronavirus disease 2019 recovered group, no coronavirus disease 2019 history group, and total subjects were extrapolated, and it was observed that the estimated time for the antibodies to reach the threshold value of the test was 214, 145, and 166 days after vaccination. CONCLUSION: It is important to make booster doses, as the CoronaVac vaccine will lose its effect after the fifth month due to the decrease in Ab levels. In addition, since the antibody levels decrease later in those who have a history of coronavirus disease 2019 infection and are vaccinated, individuals who have no previous history of coronavirus disease 2019 should be given priority for vaccination.
format Online
Article
Text
id pubmed-9779953
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Associação Médica Brasileira
record_format MEDLINE/PubMed
spelling pubmed-97799532022-12-23 Evaluation and follow-up of antibody formation after CoronaVac vaccine Çalişir, Büşra Çöplü, Nilay Yasar-Duman, Melike Kilinc, Cetin Ozbek, Ridvan Demir, Celal Ergül, Zafer Rev Assoc Med Bras (1992) Original Article OBJECTIVE: The aim of this study was to monitor the time-dependent change by evaluating the antibody levels at the 4th, 7th, 10th, 13th, and 16th weeks after the second dose of the CoronaVac vaccine. METHODS: The study group (n=65) were between 21 and 60 years old and received two doses of the CoronaVac vaccine. Blood samples were collected after 4th, 7th, 10th, 13th, and 16th weeks of the second dose of the vaccine administration. There was a coronavirus disease 2019 recovered group (n=29) who were SARS-CoV-2 real-time PCR test result positive before the vaccination period, and no coronavirus disease 2019 history group (n=36). Age, BMI, gender, smoking, comorbidity, coronavirus disease 2019 contact history, and working in the coronavirus disease 2019 service history of the individuals were recorded. RESULTS: No statistically significant difference was found in the descriptive findings of the individuals according to coronavirus disease 2019 recovered group and no coronavirus disease 2019 history group. It was observed that antibody levels in the coronavirus disease 2019 recovered group were found to be higher for each period of serum collection compared to the no coronavirus disease 2019 history group, which were statistically significant. The distribution curves of the antibody levels according to the timing of blood collection in coronavirus disease 2019 recovered group, no coronavirus disease 2019 history group, and total subjects were extrapolated, and it was observed that the estimated time for the antibodies to reach the threshold value of the test was 214, 145, and 166 days after vaccination. CONCLUSION: It is important to make booster doses, as the CoronaVac vaccine will lose its effect after the fifth month due to the decrease in Ab levels. In addition, since the antibody levels decrease later in those who have a history of coronavirus disease 2019 infection and are vaccinated, individuals who have no previous history of coronavirus disease 2019 should be given priority for vaccination. Associação Médica Brasileira 2022-12-05 /pmc/articles/PMC9779953/ /pubmed/36477105 http://dx.doi.org/10.1590/1806-9282.20221074 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Çalişir, Büşra
Çöplü, Nilay
Yasar-Duman, Melike
Kilinc, Cetin
Ozbek, Ridvan
Demir, Celal
Ergül, Zafer
Evaluation and follow-up of antibody formation after CoronaVac vaccine
title Evaluation and follow-up of antibody formation after CoronaVac vaccine
title_full Evaluation and follow-up of antibody formation after CoronaVac vaccine
title_fullStr Evaluation and follow-up of antibody formation after CoronaVac vaccine
title_full_unstemmed Evaluation and follow-up of antibody formation after CoronaVac vaccine
title_short Evaluation and follow-up of antibody formation after CoronaVac vaccine
title_sort evaluation and follow-up of antibody formation after coronavac vaccine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779953/
https://www.ncbi.nlm.nih.gov/pubmed/36477105
http://dx.doi.org/10.1590/1806-9282.20221074
work_keys_str_mv AT calisirbusra evaluationandfollowupofantibodyformationaftercoronavacvaccine
AT coplunilay evaluationandfollowupofantibodyformationaftercoronavacvaccine
AT yasardumanmelike evaluationandfollowupofantibodyformationaftercoronavacvaccine
AT kilinccetin evaluationandfollowupofantibodyformationaftercoronavacvaccine
AT ozbekridvan evaluationandfollowupofantibodyformationaftercoronavacvaccine
AT demircelal evaluationandfollowupofantibodyformationaftercoronavacvaccine
AT ergulzafer evaluationandfollowupofantibodyformationaftercoronavacvaccine